-+ 0.00%
-+ 0.00%
-+ 0.00%

Solstice Oncology raises $225 million Series A led by Canaan, RA Capital, Forbion

PUBT·09/09/2026 19:16:55
Listen to the news
Solstice Oncology raises $225 million Series A led by Canaan, RA Capital, Forbion
  • Solstice Oncology raised a USD 225 million Series A led by Canaan, with RA Capital, Forbion among participating investors.
  • Company is developing porustobart, an Fc-enhanced CTLA-4 antibody, paired with pembrolizumab for earlier-stage solid tumors.
  • Lead program targets stage II-III microsatellite-stable colon cancer, with a Phase 2 neoadjuvant trial slated to open early Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canaan Management Inc published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.